Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

Stock Information for GENFIT S.A.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GENFIT S.A.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA and Encourages Investors with Losses of $100,000 to Contact the Firm
Shareholder Alert: Robbins LLP Announces That Genfit SA (GNFT) is Being Sued for Misleading Shareholders
The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
Nasdaq Welcomes GENFIT S.A. (Nasdaq: GNFT) to The Nasdaq Stock Market

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.